サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1794495

エムポックス・ダイアグノスティックスの世界市場

Mpox Diagnostics

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
エムポックス・ダイアグノスティックスの世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

エムポックス・ダイアグノスティックスの世界市場は2030年までに22億米ドルに達する

2024年に19億米ドルと推定されるエムポックス・ダイアグノスティックスの世界市場は、2024～2030年の分析期間にCAGR 2.7%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗原検出検査は、CAGR 2.1％を記録し、分析期間終了までに15億米ドルに達すると予測されます。分子検査分野の成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は5億1,540万米ドルと推定、中国はCAGR5.0％で成長予測

米国のエムポックス・ダイアグノスティックス市場は、2024年には5億1,540万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.0%として、2030年までに4億2,610万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.0％と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界のエムポックス・ダイアグノスティックス市場- 主要動向と促進要因のまとめ

なぜMpoxの診断ソリューションに再び注目が集まっているのか？

エムポックス・ダイアグノスティックスは、疾病発生のパターンの変化、世界のサーベイランス活動の増加、および症例検出の優先順位の変化により、再び緊急性を増しています。以前は、天然痘は主に特定の地域で流行するものであったが、近年の国境を越えた感染により、タイムリーな診断が公衆衛生の優先事項となっています。診断は早期の症例隔離、アウトブレイクの追跡、接触者の追跡において中心的な役割を果たします。迅速性と正確性を確保するため、診断ツールは現在、従来の血清学的アプローチではなく、病変に基づくサンプリングに重点を置いています。

検査室での検査は、主に核酸増幅法に依存しています。これらの手法は、皮膚病変やかさぶたに含まれるウイルスDNAの存在を検出します。検査精度が最も高くなるのは、活動性の病変部から検体を採取した場合であり、血液検体から得られるウイルス量の潜在的なばらつきを避けることができます。特に、高度な検査インフラへのアクセスが限られている地域では、迅速で信頼性が高く、分散化された検査を可能にするツールに焦点が移っています。検体採取の簡素化と処理時間の短縮は、新しい診断プラットフォームにとってますます重要な設計要素となっています。

PCRベースの検査が現在の診療におけるベンチマークである理由は何か？

PCRベースの検査は依然として正確なmpox診断の基盤となっています。この方法は高感度で特異的であり、少量のウイルスDNAでも検出することができます。リアルタイムPCR検査は現在、臨床現場や公衆衛生研究所で使用されている最も信頼できるプラットフォームです。これらの検査はmpoxウイルスゲノムの特定領域を標的としており、クレード間の区別や感染状態の確認が可能です。PCRシステムには、ラボベースの分析装置から、ポイントオブケア用に設計された携帯型のカートリッジ式装置まで、いくつかのタイプが存在します。

アクセスを改善し、所要時間を短縮するために、新しい分子診断プラットフォームが登場しています。中には1時間以内で検査できるものもあり、アウトブレイク時の迅速な意思決定をサポートしています。これらのシステムは、迅速な患者のトリアージや隔離が必要な場合に特に有用です。集中型検査に加え、携帯型分子プラットフォームは、野戦病院、国境入口、移動衛生ユニットで使用するための関連性を高めています。操作の簡便さ、最小限の技術トレーニング、および既存のヘルスケア・ワークフローとの互換性に重点が置かれています。

なぜ抗原迅速検査は診断基準を満たせなかったのか？

抗原ベースの迅速診断検査は、mpox検出の信頼性がまだ証明されていないです。高い特異性を示すものもあるが、感度は一貫して低いです。ほとんどの抗原検査は、特に感染初期や治癒期の低いウイルス量を検出するのに苦労しています。無症候性または前症候性の症例を検出できないため、サーベイランスや早期対応における使用には限界があります。この制約により、単独での診断よりも補助的なスクリーニングに役割が限定されます。このような制約から、保健当局は現在、これらの検査を臨床使用することを承認していないです。

このようなギャップを受け、開発努力は改良された分子ツールや新規検出技術へとシフトしています。現在では、分子検出とデジタル表示や遠隔モニタリング機能を組み合わせた診断ツールもあります。病変写真を評価するためにAI支援画像認識を用いた実験的システムも評価されています。これらのツールは、検査施設が利用できない遠隔地での診断をサポートすることを目的としています。しかし、このようなシステムを広く使用するには、さらなる臨床的検証が必要です。

エムポックス・ダイアグノスティックス市場の成長を促す要因とは？

エムポックス・ダイアグノスティックス市場の成長は、いくつかの要因によってもたらされます。アウトブレイクの頻度の上昇と地理的な広がりにより、より迅速な検出ツールに対する需要が高まっています。ポイント・オブ・ケアPCR装置の使用拡大により、農村部や低資源環境における検査の遅れが減少しています。アウトブレイク対応キットに分子診断法を組み込むことで、早期の封じ込めが可能になっています。大がかりな検査室インフラを必要としない携帯型プラットフォームへの投資が増加し、新規参入企業の市場参入を促しています。

分散型検査やモバイル診断が重視されるようになり、発展途上国における公衆衛生の目標に合致しつつあります。検査結果をサーベイランスデータベースとリンクさせるデジタルヘルスツールの普及も、効率的なアウトブレイク管理に貢献しています。他の皮膚疾患や発熱性疾患との重複症状による鑑別診断の必要性の高まりは、高特異性アッセイの重要性を高めています。新しい診断プラットフォームの緊急使用に関する継続的な製品承認と規制ガイダンスは、製品イノベーションと地域的なアクセシビリティを支え続けています。

セグメント

診断テスト（抗原検出テスト、分子テスト）;サンプル（尿サンプル、全血サンプル、皮膚病変検体サンプル）

調査対象企業の例

  • Abbott Laboratories
  • ACON Biotech（Hangzhou）
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Cepheid（Danaher Corporation）
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer（Alinity（TM）m MPXV assay）
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37448

Global Mpox Diagnostics Market to Reach US$2.2 Billion by 2030

The global market for Mpox Diagnostics estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Antigen Detection Test, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Molecular Test segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$515.4 Million While China is Forecast to Grow at 5.0% CAGR

The Mpox Diagnostics market in the U.S. is estimated at US$515.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$426.1 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Mpox Diagnostics Market - Key Trends & Drivers Summarized

Why Is There Renewed Focus on Diagnostic Solutions for Mpox?

Mpox diagnostics have gained renewed urgency due to changing patterns in disease outbreaks, increasing global surveillance efforts, and a shift in case detection priorities. Earlier, mpox was largely endemic to specific regions, but recent cross-border transmission has made timely diagnosis a public health priority. Diagnosis plays a central role in early case isolation, outbreak tracking, and contact tracing. To ensure speed and accuracy, diagnostic tools now focus on lesion-based sampling rather than traditional serological approaches.

Laboratory testing continues to rely primarily on nucleic acid amplification methods. These techniques detect the presence of viral DNA in skin lesions and scabs. Testing accuracy is highest when samples are collected from active lesions, avoiding potential variability in viral load from blood samples. Focus has shifted toward tools that allow rapid, reliable, and decentralized testing, particularly in regions with limited access to advanced laboratory infrastructure. Simplification of sample collection and faster processing times are increasingly important design factors for new diagnostic platforms.

What Makes PCR-Based Testing the Benchmark in Current Practice?

PCR-based testing remains the foundation for accurate mpox diagnosis. This method is highly sensitive and specific, detecting even low quantities of viral DNA. Real-time PCR assays are currently the most trusted platform used in clinical settings and public health laboratories. These tests target specific regions of the mpox virus genome, allowing differentiation between clades and confirmation of infection status. Several types of PCR systems exist, ranging from lab-based analyzers to portable, cartridge-based units designed for point-of-care use.

New molecular diagnostic platforms are emerging to improve access and reduce turnaround times. Some allow testing in under one hour, supporting faster decision-making in outbreak settings. These systems are particularly useful where rapid patient triage and isolation are needed. In addition to centralized testing, portable molecular platforms are gaining relevance for use in field hospitals, border entry points, and mobile health units. Emphasis remains on operational simplicity, minimal technical training, and compatibility with existing healthcare workflows.

Why Have Rapid Antigen Tests Failed to Meet Diagnostic Standards?

Antigen-based rapid diagnostic tests have not yet proven reliable for mpox detection. While some show high specificity, their sensitivity is consistently low. Most antigen tests struggle to detect lower viral loads, especially in early or healing stages of infection. Their inability to detect asymptomatic or pre-symptomatic cases limits their use in surveillance or early response. This limitation restricts their role to supplementary screening rather than standalone diagnosis. Due to these constraints, health authorities do not currently endorse these tests for clinical use.

In response to these gaps, development efforts are shifting toward improved molecular tools and novel detection technologies. Some diagnostic tools now combine molecular detection with digital readouts or remote monitoring features. Experimental systems using AI-assisted image recognition to assess lesion photographs are also being evaluated. These tools aim to support diagnosis in remote locations where laboratory facilities are unavailable. However, such systems require further clinical validation before they can be used widely.

What Factors Are Driving Growth in the Mpox Diagnostics Market?

Growth in the mpox diagnostics market is driven by several factors. Rising frequency of outbreaks and their geographic spread has increased the demand for faster detection tools. Expanded use of point-of-care PCR devices is helping reduce testing delays in rural and low-resource settings. Integration of molecular diagnostics into outbreak response kits is enabling early containment. Increased investment in portable platforms that operate without extensive laboratory infrastructure is encouraging market participation from new manufacturers.

Greater emphasis on decentralized testing and mobile diagnostics is aligning with public health goals in developing countries. Uptake of digital health tools that link test results with surveillance databases is also contributing to efficient outbreak management. Growing need for differential diagnosis due to overlapping symptoms with other skin or febrile illnesses is raising the importance of high-specificity assays. Ongoing product approvals and regulatory guidance for emergency use of new diagnostic platforms continue to support product innovation and regional accessibility.

SCOPE OF STUDY:

The report analyzes the Mpox Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnostic Test (Antigen Detection Test, Molecular Test); Sample (Urine Sample, Whole Blood Sample, Skin Lesion Specimen Sample)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • ACON Biotech (Hangzhou)
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Cepheid (Danaher Corporation)
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer (Alinity(TM) m MPXV assay)
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mpox Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Mpox Infections Spurs Demand for Rapid and Accurate Diagnostic Solutions
    • Government Surveillance Programs and Outbreak Preparedness Plans Drive Adoption of Diagnostic Testing
    • Technological Advancements in Point-of-Care Testing Strengthen Accessibility in Resource-Limited Settings
    • Integration of PCR and Isothermal Amplification Methods Propels Market for Molecular Mpox Diagnostics
    • Public Health Emergency Declarations Throw Spotlight on Fast-Tracking of Diagnostic Product Approvals
    • Expansion of Travel Screening and Quarantine Protocols Generates Demand for Portable Test Kits
    • Increasing Role of Central Laboratories in Outbreak Control Sustains Market for High-Throughput Systems
    • Demand for Cost-Effective Testing Solutions in Developing Nations Fuels Adoption of Lateral Flow Assays
    • Healthcare Worker Safety Protocols Drive Investment in Biosafe Sample Collection and Handling Tools
    • Growth in Zoonotic Disease Surveillance Expands Market Opportunity for Cross-Species Diagnostic Platforms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mpox Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antigen Detection Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Molecular Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Whole Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Skin Lesion Specimen Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • JAPAN
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • CHINA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • EUROPE
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • FRANCE
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • GERMANY
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • INDIA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Mpox Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Mpox Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • AFRICA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030

IV. COMPETITION